Cutaneous eruptions associated with Lifileucel response in metastatic melanoma
Cutaneous morbilliform eruptions occurring after Lifileucel therapy are associated with a higher early objective response rate in metastatic melanoma patients.
The presence of purpuric morbilliform skin eruptions after Lifileucel suggests a favorable early response, providing clinicians with a potential dermatologic biomarker for efficacy.
Bizonyítékszint: Állatkísérletes. Állatmodellben vizsgálták.
Kapcsolódó jelek
- Beyond the Five-Year Milestone: Long‑term Survivorship of Melanoma Patients Treated Off‑Trial with anti‑PD‑1
- Uveal Melanoma – Trials in Disease – Overview of Information and Clinical Research
- A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma
- Melanoma Research
- The Clinical Trial Landscape for Melanoma Therapies